Americas was the largest of Revvity, Inc.’s 6 reported lines in fiscal 2025, at $505.10M — 23% of $2.15B.
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2012 | FY 2013 | FY 2014 | FY 2016 | FY 2017 | FY 2017 | FY 2018 | FY 2019 | FY 2021 | FY 2022 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | — | — | — | — | — | ||||||||||||
| Other International | $1.34B | — | — | — | — | ||||||||||||
| Europe | $1.45B | $1.37B | $402.31M | $427.44M | $481.47M | ||||||||||||
| Asia | $1.02B | $505.10M | $434.24M | $451.10M | $438.37M | ||||||||||||
| Americas | $444.46M | $683.17M | $455.83M | $477.88M | $505.10M | ||||||||||||
| China | $449.59M | — | $454.43M | $450.01M | $425.06M | ||||||||||||
| United Kingdom | $357.91M | $136.02M | $125.42M | $112.88M | $126.85M | ||||||||||||
| Germany | — | — | $193.17M | $162.58M | $177.66M | ||||||||||||
| India | — | — | — | — | — | ||||||||||||
| Japan | — | — | — | — | — | ||||||||||||
| France | — | — | — | — | — | ||||||||||||
| Italy | — | — | — | — | — | ||||||||||||
| Korea, Republic Of | — | — | — | — | — | ||||||||||||
| Total | $5.06B | $2.69B | $2.07B | $2.08B | $2.15B |
In fiscal 2025, which ended December 28, 2025, the 6 regions Revvity, Inc. reported in this breakdown added up to $2.15B. That is less than the $2.86B in its breakdown by revenue line, so these regions do not account for all of its revenue that year. Americas was the largest region, at $505.10M or 23.4% of the total, followed by Europe ($481.47M, 22.3%) and Asia ($438.37M, 20.3%). Together, the two largest regions made up 45.8% of this total.
Compared with fiscal 2024, Europe grew the fastest, rising 12.6% to $481.47M. China fell the most, down 5.5% to $425.06M.
The table also keeps 7 regions that Revvity, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 7 discontinued" beneath the table to see them. This breakdown covers 17 fiscal years between 2010 and 2025, as reported in Revvity, Inc.'s annual filings.
Life Sciences Solutions was the largest of Revvity, Inc.’s 4 reported lines in fiscal 2025, at $1.19B — 42% of $2.86B.
| Major goods/service lines | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Life Sciences Solutions | — | $1.28B | $1.20B | $1.19B |
| Immunodiagnostics | $1.11B | $787.39M | $828.63M | $869.91M |
| Life Sciences Reagents | $691.34M | — | — | — |
| Reproductive Health | $516.57M | $504.99M | $527.80M | $555.04M |
| Life Sciences Instruments | $405.55M | — | — | — |
| Applied Genomics | $393.60M | — | — | — |
| Software | — | $178.29M | $200.80M | $236.38M |
| Life Sciences Software | $196.01M | — | — | — |
| Total | $3.31B | $2.75B | $2.76B | $2.86B |
In fiscal 2025, which ended December 28, 2025, the 4 revenue lines Revvity, Inc. reported in this breakdown added up to $2.86B. That was up 3.7% from $2.76B in fiscal 2024. Life Sciences Solutions was the largest revenue line, at $1.19B or 41.8% of the total, followed by Immunodiagnostics ($869.91M, 30.5%) and Reproductive Health ($555.04M, 19.4%). Together, the two largest revenue lines made up 72.3% of this total.
Compared with fiscal 2024, Software grew the fastest, rising 17.7% to $236.38M. Life Sciences Solutions fell the most, down 0.3% to $1.19B.
The table also keeps 4 revenue lines that Revvity, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 4 discontinued" beneath the table to see them. This breakdown covers 4 fiscal years between 2023 and 2025, as reported in Revvity, Inc.'s annual filings.
Diagnostics was the largest of Revvity, Inc.’s 2 reported lines in fiscal 2025, at $1.06B — 65% of $1.64B.
| Segment | FY 2010 | FY 2011 | FY 2012 | FY 2012 | FY 2013 | FY 2014 | FY 2016 | FY 2017 | FY 2017 | FY 2018 | FY 2021 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Discovery Analytical Solutions | — | — | — | — | |||||||||||
| Discovery &Amp; Analytical Solutions | — | — | — | — | |||||||||||
| Diagnostics | $393.60M | $455.83M | $1.01B | $1.06B | |||||||||||
| Human Health | — | — | — | — | |||||||||||
| Environmental Health | — | — | — | — | |||||||||||
| Life Sciences | $691.34M | $759.78M | $539.02M | $579.88M | |||||||||||
| Total | $1.08B | $1.22B | $1.54B | $1.64B |
In fiscal 2025, which ended December 28, 2025, the 2 segments Revvity, Inc. reported in this breakdown added up to $1.64B. That is less than the $2.86B in its breakdown by revenue line, so these segments do not account for all of its revenue that year. Diagnostics was the largest segment, at $1.06B or 64.6% of the total, followed by Life Sciences ($579.88M, 35.4%).
Compared with fiscal 2024, Life Sciences grew the fastest, rising 7.6% to $579.88M.
The table also keeps 4 segments that Revvity, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 4 discontinued" beneath the table to see them. This breakdown covers 15 fiscal years between 2010 and 2025, as reported in Revvity, Inc.'s annual filings.
Revvity, Inc. (RVTY) breaks its revenue down by region, revenue line and segment. In fiscal 2025, its largest region was Americas, with $505.10M or 23.4% of the total, followed by Europe at $481.47M (22.3%).
Americas was Revvity, Inc.'s largest region in fiscal 2025, with $505.10M in revenue, 23.4% of the $2.15B reported across its 6 regions.
Life Sciences Solutions was Revvity, Inc.'s largest revenue line in fiscal 2025, with $1.19B in revenue, 41.8% of the $2.86B reported across its 4 revenue lines.
Diagnostics was Revvity, Inc.'s largest segment in fiscal 2025, with $1.06B in revenue, 64.6% of the $1.64B reported across its 2 segments.
Of the Revvity, Inc. regions reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Europe grew the fastest, rising 12.6% from $427.44M to $481.47M.
Every figure is taken from Revvity, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2010 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.